MedPath

Controlled Fluid Resuscitation in Sepsis

Not Applicable
Conditions
Sepsis
Registration Number
NCT03214913
Lead Sponsor
Ruijin Hospital
Brief Summary

To evaluate two different strategy of fluid resuscitation in sepsis patients

Detailed Description

Early goal-directed fluid therapy (EGDT) had been regarded as an important fluid therapy strategy in early sepsis or septic shock patients. In recent years, several randomized control studies showed the EGDT therapy cannot make a better outcome in sepsis patients compared to the standard therapy. A strategy of controlled fluid resuscitation had showed good outcome in critical illness such as severe acute pancreatitis, major trauma. But many aspects of the so-called controlled fluid resuscitation remained controversial. In a previous study on severe acute pancreatitis, we described a bundle of controlled fluid resuscitation which had showed an ideal result with higher survival rate. So, we are going to use the bundle on sepsis patients, and to see if it can bring a better out come in sepsis patients compared to the EGDT strategy. This study aims to determine a better strategy of fluid resuscitation in sepsis patients

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
550
Inclusion Criteria
  • 1.sepsis patients in accordance with the Sepsis 3.0 definition(SOFA increase ≥2 compared to the baseline,due to infection )
  • 2.the first blood lactate in our hospital is ≥ 4mmol/L or MAP<90mmHg after 20ml/kg fluid bolus
  • 3.the shock is diagnosed within 24hrs after onset
Exclusion Criteria
    • 1.<18 years old
  • 2.Pregnancy
  • 3 with co-morbidity such as AE-COPD, stroke, seizure, lung edema, acute coronary syndrome
  • 4 with contra-indication of CVC(central venous catheter) placement
  • 5 trauma or major burn
  • 6 poisoning
  • 7 any cancer receiving chemotherapy
  • 8.immunosuppression (for organ transplantation or disease of immune system)
  • 9.acute pancreatitis
  • 10.relapse sepsis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Mortalitythe 28th day from enrolled

Mortality

Secondary Outcome Measures
NameTimeMethod
Mortalitythe 60th day from enrolled

Mortality

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.